PET and the role of in vivo molecular imaging in personalized medicine.
In order for personalized medicine to become a clinical reality a number of hurdles, both technological and regulatory in nature, need to be addressed. Our ability to image biological and pathological processes at a molecular level using positron emission tomography (PET) imaging offers an unparalleled opportunity to radically reform the manner in which a disease is diagnosed and managed. The degree to which current innovations in PET science will translate into clinical practice, thereby impacting upon personalized medicine, is discussed.
Pither
Richard
R
Amersham Health, Little Chalfont, Buckinghamshire, UK. Richard.pither@amersham.com
D003937:Diagnosis, Differential; D019788:Fluorodeoxyglucose F18 / Q000737:chemistry / Q000378:metabolism; D020022:Genetic Predisposition to Disease; D006801:Humans; D025202:Molecular Diagnostic Techniques; D019275:Radiopharmaceuticals / Q000737:chemistry / Q000378:metabolism; D014055:Tomography, Emission-Computed
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18